
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
| Synthetic peptide | 3 |
| Chemical drugs | 1 |
| AAV based gene therapy | 1 |
Target |
Mechanism CCR5 antagonists |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GLUT1 stimulants [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Mar 2023 |
Sponsor / Collaborator |
Start Date20 Mar 2020 |
Sponsor / Collaborator |
Start Date17 Oct 2018 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Thioraviroc ( CCR5 ) | HIV Infections More | Phase 1 |
Ferul enanthate ( ATP synthase x GLUT1 ) | Alzheimer Disease More | Preclinical |
DB02 ( RT ) | HIV Infections More | Preclinical |
Peptide targeting LBP (Kunming Institute of Zoology) ( LBP ) | Depressive Disorder More | Preclinical |
OH-CATH30 | Conjunctivitis, Bacterial More | Preclinical |





